Formycon AG (WBO:FYB) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:FYB Formycon AG WBO:FYB
39 GF Score
Price €18.30
GF Value €37.04
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Formycon AG Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

WBO:FYB
39GF Score
Formycon AG WBO:FYB
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Formycon AG (WBO:FYB) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €18.30 is trading 50.6% below its estimated GF Value™ of €37.04. GuruFocus considers Formycon AG to be Possible Value Trap.

Key valuation signals for WBO:FYB:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €37.04 vs. price of €18.30 (50.6% below fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the WBO:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Other Exchanges 0W4N:UKFYB:Germany
Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
39GF Score

Get the complete analysis for WBO:FYB

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.30
Price
€37.04
GF Value